<DOC>
	<DOCNO>NCT00414206</DOCNO>
	<brief_summary>This Phase II randomize , double-masked study compare safety efficacy ATG003 ( mecamylamine HCl ) 1.0 % 0.3 % ophthalmic solution placebo patient neovascular ( `` wet '' ) age-related macular degeneration ( NV-AMD ) .</brief_summary>
	<brief_title>Safety Efficacy ATG003 Patients With Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
</DOC>